Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

December 31, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

doxycycline

capsule, 100 mg, b.i.d., daily for 1 year

DRUG

rifampicin

capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)

DRUG

Placebo matched to doxycycline

Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months

DRUG

Placebo matched to Rifampin

Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.

Trial Locations (1)

L8M1W9

St.Peter's Hospital, Hamilton

All Listed Sponsors
collaborator

The Physicians' Services Incorporated Foundation

OTHER

lead

Hamilton Health Sciences Corporation

OTHER

NCT00439166 - Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid | Biotech Hunter | Biotech Hunter